GPC Biotech’s mission was to discover and develop novel anti-cancer drugs. The founding team raised two private financing rounds in 1997 and 1999, acquired a Boston-based drug discovery company, took GPC public in 2000 and listed GPC on Nasdaq in 2004. It developed an anti-cancer drug through clinical phase 3 and filed for market registration. In 2009, GPC Biotech merged with the US-based company Agennix Inc.